Advertisement
ADPT vs AXON
Which Stock Would AI Choose? Adaptive Biotechnologies (ADPT) vs. Axon Enterprise (AXON) Stock Comparison
Key Takeaways
- ADPT has shown stronger recent momentum, with consecutive revenue beats and rising guidance, while AXON has faced a guidance cut and a sharp post-earnings decline.
- ADPT is advancing a plan to separate its profitable MRD business from its earlier-stage Immune Medicine unit, a potential value-unlocking catalyst.
- AXON still posts robust underlying growth, but delayed federal counter-drone deployments and margin pressure have dampened near-term sentiment.
- Tickeron AI Verdict: Based on trend consistency, positive estimate revisions, and clearer near-term catalysts, Tickeron's AI currently favors ADPT over AXON in this comparison.
- For deeper context, explore ADPT Major News and ADPT Today's Price Move, as well as AXON Major News and AXON Today's Price Move.
- To see how automated strategies are navigating these and other tickers, explore Trending AI Robots.
Introduction
This comparison examines two very different growth stories: ADPT (Adaptive Biotechnologies), a commercial-stage biotechnology company focused on immune-system diagnostics, and AXON (Axon Enterprise), a public-safety technology leader known for Tasers, body cameras, and software. While they operate in unrelated sectors, both are high-growth, momentum-sensitive names that attract investors weighing clinical and product catalysts against valuation and execution risk. A stock comparison between the two is most relevant for growth-oriented traders and investors who monitor relative performance, estimate revisions, and market positioning to decide where current momentum and catalysts are strongest.
ADPT Overview and Recent Performance
Adaptive Biotechnologies (ADPT) translates the genetics of the adaptive immune system into clinical diagnostics and drug-discovery tools. Its two segments are Minimal Residual Disease (MRD) testing — which detects small amounts of cancer remaining after treatment, primarily through its clonoSEQ platform — and Immune Medicine. In recent weeks, the company has delivered consecutive quarterly revenue beats and raised its full-year MRD revenue outlook multiple times, with the latest guidance pointing to roughly $268 million to $278 million for 2026. Management has also announced plans to separate the profitable MRD business from Immune Medicine, a move widely viewed as a potential value-unlocking catalyst. The stock has traded well above its 52-week low and posted substantial gains over the past year, reflecting improving commercial traction and a re-rating in market sentiment.
AXON Overview and Recent Performance
Axon Enterprise (AXON) supplies conducted-energy weapons (Tasers), body cameras, and an expanding software ecosystem to law enforcement and public-safety agencies. Its recent market activity has been turbulent: the company reported record quarterly revenue up roughly 28% year over year, but the figure missed consensus estimates, and management lowered its full-year growth outlook to about 30% from a prior 32% to 34%. The revision stemmed from delays in three federal counter-drone (Dedrone) deployments worth about $130 million. Shares fell sharply in response, and the stock has lagged significantly in 2026. At the same time, Axon announced an additional $1.2 billion investment in drone maker Skydio, raising its stake and securing exclusive public-safety distribution rights. Underlying software demand remains strong, with annual recurring revenue up about 40%.
Trending AI Robots
Tickeron maintains a marketplace of hundreds of AI trading bots that collectively monitor thousands of different tickers. Because these bots vary widely in trading style, strategy, timeframe, performance history, and the specific tickers they follow, only the most suitable for current market conditions are featured in the curated Trending AI Robots section. This curated list is designed to help traders surface strategies whose statistical profiles and recent performance align with today's environment, rather than sifting through the full catalog manually. Whether a bot emphasizes trend-following, mean reversion, or short-term momentum, each carries its own track record and risk characteristics. Investors interested in applying a data-driven approach to names like ADPT and AXON may find value in reviewing the Trending AI Robots page to identify strategies currently in favor.
Head-to-Head Comparison
The two companies differ sharply in business model and risk profile. ADPT is a smaller-cap diagnostics and drug-discovery company that remains largely unprofitable on a GAAP (Generally Accepted Accounting Principles) basis, though its MRD segment has reached profitability and is driving revenue growth. Its key variables are clinical adoption, reimbursement, and the execution of the planned segment separation. AXON, by contrast, is a larger, more diversified hardware-and-software business with positive net income and substantial recurring revenue, but it carries exposure to government procurement timing, hardware margins, and integration risk from its drone expansion. On momentum, ADPT has benefited from rising estimates and guidance raises, while AXON has absorbed estimate cuts and a sharp sell-off. On stability, AXON's recurring software base is a structural advantage, yet its near-term catalysts appear less defined than ADPT's separation and MRD adoption story.
Tickeron AI Verdict
Weighing observable factors such as trend consistency, estimate-revision direction, near-term catalysts, and relative positioning, Tickeron's AI would likely favor ADPT over AXON in the current environment. ADPT's combination of rising revenue guidance, consecutive beats, and a clearly defined value-unlocking catalyst supports a more constructive trend profile. AXON retains a compelling long-term growth trajectory, but its recent guidance cut, margin compression, and negative price momentum weigh on its near-term relative positioning. These assessments are probabilistic and based on current data rather than definitive forecasts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADPT is a StrongBuy and AXON is a Buy.
Momentum Indicator for ADPT turns positive, indicating new upward trend
ADPT saw its Momentum Indicator move above the 0 level on October 26, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned positive. In 76 of the 84 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ADPT just turned positive on October 27, 2026. Looking at past instances where ADPT's MACD turned positive, the stock continued to rise in 48 of 54 cases over the following month. The odds of a continued upward trend are 89%.
ADPT moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ADPT crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +4.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADPT advanced for three days, in 237 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 63 cases where ADPT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
ADPT broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ADPT entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.246) is normal, around the industry mean (67.298). P/E Ratio (-69.950) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (13.966) is also within normal values, averaging (9.775).
The Tickeron Seasonality Score of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ADPT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
AXON's RSI Oscillator slumps into oversold zone
The RSI Oscillator for AXON moved into overbought territory on November 06, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 55 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 32 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 80 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (5.050). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.247). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
ADPT | AXON | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 18 Undervalued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 80 | |
SMR RATING 1..100 | 97 | 81 | |
PRICE GROWTH RATING 1..100 | 35 | 65 | |
P/E GROWTH RATING 1..100 | 79 | 81 | |
SEASONALITY SCORE 1..100 | 27 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ADPT's Valuation (18) in the Hospital Or Nursing Management industry is significantly better than the same rating for AXON (90) in the Biotechnology industry. This means that ADPT’s stock grew significantly faster than AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (80) in the Biotechnology industry is in the same range as ADPT (100) in the Hospital Or Nursing Management industry. This means that AXON’s stock grew similarly to ADPT’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as ADPT (97) in the Hospital Or Nursing Management industry. This means that AXON’s stock grew similarly to ADPT’s over the last 12 months.
ADPT's Price Growth Rating (35) in the Hospital Or Nursing Management industry is in the same range as AXON (65) in the Biotechnology industry. This means that ADPT’s stock grew similarly to AXON’s over the last 12 months.
ADPT's P/E Growth Rating (79) in the Hospital Or Nursing Management industry is in the same range as AXON (81) in the Biotechnology industry. This means that ADPT’s stock grew similarly to AXON’s over the last 12 months.
| ADPT | AXON | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 86% |
| Stochastic ODDS (%) | 3 days ago 79% | 3 days ago 82% |
| Momentum ODDS (%) | 3 days ago 90% | 3 days ago 72% |
| MACD ODDS (%) | 3 days ago 89% | 3 days ago 84% |
| TrendWeek ODDS (%) | 3 days ago 85% | 3 days ago 69% |
| TrendMonth ODDS (%) | 3 days ago 86% | 3 days ago 71% |
| Advances ODDS (%) | 3 days ago 86% | 13 days ago 74% |
| Declines ODDS (%) | 7 days ago 85% | 3 days ago 70% |
| BollingerBands ODDS (%) | 3 days ago 86% | 3 days ago 79% |
| Aroon ODDS (%) | 3 days ago 84% | 3 days ago 80% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ADPT’s FA Score shows that 1 FA rating(s) are green while AXON’s FA Score has 0 green FA rating(s).
- ADPT’s FA Score: 1 green, 4 red.
- AXON’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ADPT’s TA Score shows that 5 TA indicator(s) are bullish while AXON’s TA Score has 4 bullish TA indicator(s).
- ADPT’s TA Score: 5 bullish, 4 bearish.
- AXON’s TA Score: 4 bullish, 4 bearish.
Price Growth
ADPT (@Medical Specialties) experienced а +5.03% price change this week, while AXON (@Aerospace & Defense) price change was -26.83% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -6.42%. For the same industry, the average monthly price growth was -7.90%, and the average quarterly price growth was +34.49%.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -3.18%. For the same industry, the average monthly price growth was -9.42%, and the average quarterly price growth was -20.28%.
Reported Earning Dates
ADPT is expected to report earnings on Feb 16, 2027.
AXON is expected to report earnings on Mar 02, 2027.
Industries' Descriptions
@Medical Specialties (-6.42% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Aerospace & Defense (-3.18% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
Advertisement
ADPT and
Correlation & Price change
A.I.dvisor indicates that over the last year, ADPT has been loosely correlated with AXON. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ADPT jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To ADPT | 1D Price Change % | ||
|---|---|---|---|---|
| ADPT | 100% | +4.29% | ||
| AXON - ADPT | 56% Loosely correlated | -18.18% | ||
| PSNL - ADPT | 53% Loosely correlated | +1.54% | ||
| GH - ADPT | 51% Loosely correlated | -1.67% | ||
| NTRA - ADPT | 51% Loosely correlated | -14.59% | ||
| ARRY - ADPT | 50% Loosely correlated | +10.47% | ||
More | ||||